Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771607 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| SCHEMBL1609328 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1S1PR5SLC6A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19638092 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| Hydrochloric Acid SCHEMBL613075 | 0.98 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1S1PR5LMNA | |
| SCHEMBL13740434 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL934458 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL13739335 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| Hydrochloric Acid SCHEMBL28596153 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1S1PR5CYP1A2HSD11B1 | |
| SCHEMBL3842738 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1SLC6A1CYP1A2CYP2D6 | |
| Aniline SCHEMBL27948912 | 0.85 | ALDH1A1 (0.55) | ALDH1A1SLC6A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575947-A1 | 2-OXOPYRIDIN-3-YL THIA(DI)AZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | Amgen Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004060890-A1 | 2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES | AMGEN INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-0585314-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS. | NOVO NORDISK AS (DK) | 1994-03-09 | — | — | EP | claimed |
| WO-1992020658-A1 | NOVEL HETEROCYCLIC CARBOXYLIC ACIDS | NOVO NORDISK A/S (DK) | 1992-11-26 | — | — | WO | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| EP-0522082-A4 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | — | 1993-06-09 | — | — | EP | disclosed |
| WO-1993003725-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-04 | — | — | WO | disclosed |
| EP-0522082-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE. | GLASKY ALVIN J (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5147882-A | Cardiovascular disorders | KARL THOMAE GMBH (DE) | 1992-09-15 | — | — | US | disclosed |
| US-5091432-A | Synergistic | SPECTRUM PHARMACEUTICALS, INC. | 1992-02-25 | — | — | US | disclosed |
| WO-1991014434-A1 | MULTI-FUNCTIONAL PHARMACEUTICAL COMPOUNDS AND METHODS OF USE | GLASKY ALVIN J (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4162322-A | ANTISECRETORY | SCIENCE UNION ET CIE, SOCIETE FRANCAISE DE RECHERCHE MED. (FR) | 1979-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | SMN1; SMN2 4302/4885ALDH1A1 3965/4885S1PR5 3284/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | SMN1; SMN2 3277/4885ALDH1A1 4740/4885S1PR5 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.